Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment

A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date

Hyponatremia is the most common electrolyte disorder in clinical practice, which may lead to life-threatening complications. Several lines of evidence suggest that hyponatremia is associated not only with significant increases in length of stay, cost, and financial burden, but also with increased morbidity and mortality. Hyponatremia is also considered to be a negative prognostic factor in patients with heart failure and cancer. Although multiple therapeutic methods are available for treating hyponatremia, most have some limitations, such as poor compliance, rapid correction of serum Na⁺, other negative side effects and high cost. Given these limitations, identifying novel therapies for hyponatremia is essential. Recent clinical studies have shown that SGLT-2 inhibitors (SGLT 2i) significantly increased serum Na⁺ levels and were well tolerated by patients who underwent this treatment. Therefore, oral administration of SGLT 2i appears to be an effective treatment for hyponatremia. This article will briefly review the etiology of hyponatremia and integrated control of sodium within the kidney, current therapies for hyponatremia, potential mechanisms and efficacy of SGLT 2i for hyponatremia, and the benefits in cardiovascular, cancer, and kidney disease by regulating sodium and water balance.

Breviscapine prevents downregulation of renal water and sodium transport proteins in response to unilateral ureteral obstruction

OBJECTIVES

Our recent report indicates that breviscapine play a protective role of the kidney by down-regulating transforming growth factor-β1(TGF-β1), α-smooth muscle actin (α-SMA) and alleviating interstitial fibrosis following unilateral ureteral obstruction (UUO). In this study, we investigate the effect of breviscapine on changes of renal water and sodium transport proteins in response to UUO.

MATERIALS AND METHODS

Male Sprague-Dawley rats were divided into 3 groups, sham group, UUO group and UUO treat with breviscapine. After 4, 7 and 14 days, histologic changes and interstitial collagen were determined microscopically following hematoxylin and eosin (H&E) and Masson's trichrome staining. The expression of Aquaporins (AQP-2) and γ-epithelial sodium channel (γ-ENaC) were investigated using immunohistochemistry and Western blot in each group.

RESULTS

Breviscapine treatment decrease the tubular injury index and the degree of interstitial collagen deposition significantly compared with the UUO group (P<0.05). Breviscapine treatment also significantly reduced downregulation of AQP2 and γ-ENaC compared to those subjected to the same time course of obstruction in UUO group (P<0.05).

CONCLUSION

These results demonstrate that breviscapine could prevent downregulation of renal water and sodium transport proteins in response to UUO so as to protect obstructed kidney.